To prospectively evaluate the use of intravenous rt-PA in Canada. Thrombolytic therapy for acute stroke in Canada was conditionally approved in 1999; this study was a mandated by the federal government as a condition for full approval.
- Tissue plasminogen activator (Activase®)Drug
Intervention Desc: Thrombolytic
Open label, multi-center post-marketing study.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Clinical outcome at 3 months assessed by the modified Rankin Scale score, ASPECT scores measured by investigators compared with a panel of experts, and symptomatic intracerebral hemorrhage related to rtPA.|